Search
Search results
18 results found
IMPROVE-DiCE, a 2-Part, Open-Label, Phase 2a Trial Evaluating the Safety and Effectiveness of Ninerafaxstat in Patients With Cardiometabolic Syndromes.
Hundertmark, Moritz J, Sarah M Birkhoelzer, Clara Portwood, Adrienne G Siu, Violet Matthews, Andrew J Lewis, James Grist, et al. 2026. “IMPROVE-DiCE, a 2-Part, Open-Label, Phase 2a Trial Evaluating the Safety and Effectiveness of Ninerafaxstat in Patients With Cardiometabolic Syndromes.”. Circulation 153 (8): 550-63.
Circulating metabolites, genetics and lifestyle factors in relation to future risk of type 2 diabetes.
Li, Jun, Jie Hu, Huan Yun, Zhendong Mei, Xingyan Wang, Kai Luo, Marta Guasch-Ferré, et al. 2026. “Circulating Metabolites, Genetics and Lifestyle Factors in Relation to Future Risk of Type 2 Diabetes.”. Nature Medicine 32 (2): 660-70.
Organ-specific proteomic aging clocks predict disease and longevity across diverse populations.
Wang, Yunhe, Sihao Xiao, Bowen Liu, Rongtao Jiang, Yuxi Liu, Yian Hang, Li Chen, et al. 2025. “Organ-Specific Proteomic Aging Clocks Predict Disease and Longevity across Diverse Populations.”. Nature Aging.
Collaborations
Team
News
Contact
Human plasma proteomic profile of clonal hematopoiesis.
Yu, Zhi, Amélie Vromman, Ngoc Quynh H Nguyen, Art Schuermans, Linke Li, Thiago Rentz, Tetsushi Nakao, et al. 2025. “Human Plasma Proteomic Profile of Clonal Hematopoiesis.”. Nature Communications 16 (1): 11688.
Plasma proteomics and incident coronary heart disease.
Huber, Matthew P, Jennifer A Brody, Colleen M Sitlani, Thomas R Austin, Usman A Tahir, Shuliang Deng, Devendra Meena, et al. 2026. “Plasma Proteomics and Incident Coronary Heart Disease.”. Communications Medicine 6 (1): 98.